Dr Ram Bishwakarma, chairman of Covid Strategy Group, CSIR, told NDTV that the emergency use of the mark drug Malnupiravir – an oral antiviral drug for the treatment of mild to moderate Covid-19 – was probably “within days”. Today. The drug is for adults who are at serious risk of COVID-19 or hospitalization. Another pill from Pfizer may take some more time for Paxlovid, he added.
The two drugs will make a difference, he said, and “as we move from epidemic to epidemic, these are going to be more important than vaccinations.”
Describing the drugs as “the final nail in the coffin of the virus by science”, he said, “I think Malnupiravi will already be available to us.
He said Malnupiravir’s data was “sitting with the regulator” here before the UK regulator’s approval. “So the SECs are already looking into it. And I think they will get approval soon. And so, it would be safe to say that within the next one month, there will be a decision on the approval of Mark Drugs.”
Pfizer says that according to clinical trials, its paxlovid reduces the risk of hospitalization or death in high-risk adults by 89 percent.
Merck has already entered into agreements with five companies “and Pfizer will do the same as Merck has given licenses to several companies because Pfizer will have to use Indian capabilities to manufacture the drugs needed for global use”.
He said the cost would be much lower than the 700 700 considered in the United States for the Mark vaccine “because in the United States it is expensive for a variety of other reasons and not for production costs.”
“I think when the Indian government is effective here, they will buy a lot from these companies and of course, they will have a dual pricing system and a stagnant pricing system,” he said.
He said that initially it could be “2000 to 3000 or 4000 rupees per treatment cycle, then it will come down to 500 to 600 or 1000 rupees”.